Much of ULTY's payout is return of capital, leading to capital depletion and negative total returns. Read why I see no ...

Upstart ( NASDAQ: UPST) expects $587.3 million in net proceeds ($675.5 million if the option is exercised). About $48 million ...

Chevron's Q2'25 results beat estimates with record production, strong cash flow, and growth prospects from the Hess ...

National HealthCare's fundamentals are robust, with strong earnings, revenue, and margin growth. Read why NHC stock is a Buy.

IPO trends, insights on insider selling, and potential opportunities for contrarian investors amid. See more on INR stock.

Thermo Fisher saw accelerating revenue growth in pharma/biotech, AI-driven cost efficiencies, and attractive valuations. See ...

Choose MUC CEF for targeted California muni bond exposure, which offers tax-advantaged income, high yield, and a wide ...

lululemon's stock has dropped so much because the board is numbers-driven and there's nobody looking after the creative side.

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Evolv Technologies appears to be in a good way with new management, outperforming peers. Click here to read the earnings ...

Potential Fed rate cuts could boost housing demand, providing a favorable macro backdrop for D.R. Horton. Read why I remain ...

Banco Bradesco's strong results face challenges like rising SME/rural lending risks amid Brazil's credit crunch. See here for ...